SG11201505818WA - Treatment of multiple sclerosis with laquinimod - Google Patents
Treatment of multiple sclerosis with laquinimodInfo
- Publication number
- SG11201505818WA SG11201505818WA SG11201505818WA SG11201505818WA SG11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA SG 11201505818W A SG11201505818W A SG 11201505818WA
- Authority
- SG
- Singapore
- Prior art keywords
- laquinimod
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765394P | 2013-02-15 | 2013-02-15 | |
| US201361911106P | 2013-12-03 | 2013-12-03 | |
| PCT/US2014/016278 WO2014127139A1 (en) | 2013-02-15 | 2014-02-13 | Treatment of multiple sclerosis with laquinimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505818WA true SG11201505818WA (en) | 2015-08-28 |
Family
ID=51351655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505818WA SG11201505818WA (en) | 2013-02-15 | 2014-02-13 | Treatment of multiple sclerosis with laquinimod |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140235670A1 (enExample) |
| EP (1) | EP2956137A4 (enExample) |
| JP (1) | JP2016510343A (enExample) |
| KR (1) | KR20150119227A (enExample) |
| CN (1) | CN105163737A (enExample) |
| AU (1) | AU2014216199A1 (enExample) |
| BR (1) | BR112015019564A2 (enExample) |
| CA (1) | CA2900503A1 (enExample) |
| CL (1) | CL2015002181A1 (enExample) |
| EA (1) | EA201591507A1 (enExample) |
| HK (2) | HK1218251A1 (enExample) |
| IL (1) | IL240014A0 (enExample) |
| MX (1) | MX2015010296A (enExample) |
| PE (1) | PE20151526A1 (enExample) |
| SG (1) | SG11201505818WA (enExample) |
| TW (1) | TW201442709A (enExample) |
| UY (1) | UY35328A (enExample) |
| WO (1) | WO2014127139A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| US10537566B2 (en) | 2014-10-16 | 2020-01-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US10091217B2 (en) | 2016-06-21 | 2018-10-02 | Logrhythm, Inc. | Risk based priority processing of data |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| US12370233B2 (en) | 2016-08-31 | 2025-07-29 | Mapi Pharma Ltd. | Depot systems comprising glatiramer acetate |
| WO2018178973A1 (en) * | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| US20230296628A1 (en) * | 2020-07-09 | 2023-09-21 | Oklahoma Medical Research Foundation | Biomarkers for Identifying Relapses in Multiple Sclerosis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US7989473B2 (en) * | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2009009529A1 (en) * | 2007-07-11 | 2009-01-15 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| JP2012512165A (ja) * | 2008-12-11 | 2012-05-31 | バイオヴィスタ，インコーポレイテッド | 四環系ピラジノインドールを用いた多発性硬化症の治療方法 |
| DK2442651T3 (en) * | 2009-06-19 | 2015-09-21 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| SG10201509831XA (en) * | 2010-12-07 | 2015-12-30 | Teva Pharma | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| JP2014521659A (ja) * | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| US20140107154A1 (en) * | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
-
2014
- 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
- 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
- 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
- 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
- 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
- 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
- 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
- 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
- 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
- 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
- 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
- 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
- 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
- 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
- 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
- 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
- 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
-
2015
- 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
- 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
-
2017
- 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1218251A1 (zh) | 2017-02-10 |
| EA201591507A1 (ru) | 2015-12-30 |
| TW201442709A (zh) | 2014-11-16 |
| CN105163737A (zh) | 2015-12-16 |
| PE20151526A1 (es) | 2015-11-20 |
| MX2015010296A (es) | 2016-05-05 |
| WO2014127139A1 (en) | 2014-08-21 |
| UY35328A (es) | 2014-09-30 |
| CA2900503A1 (en) | 2014-08-21 |
| US20180064702A1 (en) | 2018-03-08 |
| JP2016510343A (ja) | 2016-04-07 |
| BR112015019564A2 (pt) | 2017-07-18 |
| AU2014216199A1 (en) | 2015-09-03 |
| US20140235670A1 (en) | 2014-08-21 |
| EP2956137A1 (en) | 2015-12-23 |
| KR20150119227A (ko) | 2015-10-23 |
| IL240014A0 (en) | 2015-09-24 |
| HK1218254A1 (zh) | 2017-02-10 |
| CL2015002181A1 (es) | 2016-06-03 |
| EP2956137A4 (en) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| IL245408B (en) | Converted benzamides for the treatment of arthropods | |
| IL241101B (en) | Medicinal uses of empagliflozin | |
| SG11201507121RA (en) | Treatment of cataplexy | |
| IL241102A0 (en) | Medicinal uses of empagliflozin | |
| LT2981271T (lt) | Empagliflozino terapinis panaudojimas | |
| IL240014A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| IL245373A0 (en) | Treatment of glaucoma by laquinimod | |
| IL241096B (en) | Treatment methods | |
| IL243486A0 (en) | Treatment of multiple sclerosis using a combination of laquinimod and flupirtine | |
| IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
| ZA201601626B (en) | Treatment of gases | |
| GB2525530B (en) | Treatment of hard surfaces | |
| IL246078A0 (en) | Treatment of multiple sclerosis by a combination of laquinimod and triflunomide | |
| HK1225291A1 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment | |
| GB201306411D0 (en) | Treatment of inflammatory conditions | |
| AU2013901359A0 (en) | Methods of Treatment |